Trials / Terminated
TerminatedNCT01685255
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epacadostat | |
| DRUG | tamoxifen |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2014-10-23
- Completion
- 2014-10-23
- First posted
- 2012-09-14
- Last updated
- 2019-03-11
Locations
49 sites across 6 countries: United States, Australia, Canada, Russia, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT01685255. Inclusion in this directory is not an endorsement.